RecallDepth
Class II Terminated

MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01

Company
Amgen, Inc.
Recall Initiated
May 2, 2022
Posted
May 18, 2022
Recall Number
D-0855-2022
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
15,823
Firm Location
Thousand Oaks, CA, United States

Reason for Recall

Defective container: loose crimp defect, potential loss of container integrity.

Distribution

Nationwide in the USA, Egypt and Lithuania.

Lot / Code Info

Lots: 1142258, 1143196, Exp. 09/24

More recalls by Amgen, Inc.

View all recalls by this company →

Other recent Class II Drug recalls